Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG206 in Primary Sjögren's Syndrome Phase II Study
CTR20260643Phase 2Active
- Sponsor
- Affinity Biopharma
- Start
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206 in primary Sjögren's syndrome, sponsored by Affinity Biopharma. Started Mar 2026; status: active.
02
Drugs
ESG206
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on CTR20260643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260643.